Physician profile
Mareena Miller
NPI 1750824058
$3,365.17
in general payments reported to CMS, 2019-2025
32 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $805 · 2022: $793 · 2023: $447 · 2024: $166 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $504.63 | 2021-2022 | |
| Stryker Corporation | $339.89 | 2023 | Mako |
| Alkermes, INC. | $241.79 | 2025 | Lybalvi, Aristada |
| Biohaven Pharmaceuticals, INC. | $222.32 | 2021 | |
| Abbvie INC. | $200.53 | 2021-2024 | |
| Zimmer Biomet Holdings, INC. | $192.02 | 2025 | Rosa |
| Galderma Laboratories, L.P. | $186.52 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $154.89 | 2025 | |
| Janssen Pharmaceuticals, INC | $145.90 | 2025 | Invega Sustenna, Spravato |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2022 | |
| Boston Scientific Corporation | $113.13 | 2021-2023 | Superion Indirect Decompression System |
| E.R. Squibb & Sons, L.L.C. | $110.22 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $110.10 | 2021-2025 | Qelbree |
| Exactech, INC. | $104.86 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $91.63 | 2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $73.95 | 2021 | |
| Eisai INC. | $46.70 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.80 | 2025 | Caplyta |
| Stimwave Technologies Incorporated | $41.06 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $37.95 | 2025 | Austedo Xr |
| Biodelivery Sciences International, INC. | $35.64 | 2021 | |
| Vanda Pharmaceuticals INC. | $34.96 | 2025 | Fanapt |
| Nevro Corp. | $28.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.37 | 2021 | |
| Amgen INC. | $23.04 | 2021 | |
| Axsome Therapeutics, INC. | $22.57 | 2025 | Auvelity |
| Bausch Health US, LLC | $20.96 | 2025 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $20.55 | 2025 | Trintellix |
| Lundbeck LLC | $19.01 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.51 | 2023 | Xifaxan |
| Avanos Medical | $15.96 | 2024 | On-Q* Pump and Accessories |
| Scilex Pharmaceuticals INC. | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mareena Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.